Biotechnology Company

Batu Biologics, Inc.

17%

Funding Goal $3,000,000
Funding Raised So Far $0
Funding Commitments $500,000
Funding Remaining $2,500,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview

Batu Biologics is an immuno-oncology company focused on the development and commercialization of novel therapies that target the “Achilles Heel of Cancer”: the tumor blood vessels.


Angiogenesis, or the process of new blood vessel formation, is essential for the growth and metastasis of solid tumors. Tumors cannot grow larger than 1-2 millimeter in diameter without stimulating new blood vessels to feed them. Blocking this process has led to the development of multibillion-dollar blockbuster drugs such as Avastin ($7 billion 2015), Sunitinib ($1.1 billion 2016), and Revlimed ($3.2 billion 2011). Unfortunately these drugs target only one pathway of the angiogenesis process, and as a result tumor remissions are temporary, and in many cases not sustainable.

Batu Biologics’ flagship therapeutic, ValloVax™, is based on harnessing the immune system’s ability to selectively seek and destroy tumor-associated blood vessels, while sparing non-malignant blood vessels. In contrast to previous anti-angiogenic approaches, ValloVax™ stimulates the immune system to attack multiple pathways necessary for angiogenesis, thus having the potential for superior efficacy in the treatment of solid tumors. Batu Biologics sees the ValloVax™ platform as a powerful new immunotherapeutic approach to treating cancer that works synergistically with several already FDA approved drugs, and plans to develop the program clinically for multiple solid tumor indications.

Batu Biologics has recently received FDA regulatory clearance of our Investigational New Drug Application, enabling the Company to proceed with a Phase I study for patients with metastatic non small cell lung cancer.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Investor Sign Up
Investor Log In

Business Summary

Company Age
Employees
Sub-Industry
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Management

Samuel Wagner
Chief Executive Officer
Samuel W......

Samuel W...... is a founder of Batu Biologics and has served as its President and Chief Executive Officer since January of 2014. Mr. W...... studied engineering at an honors level at the University of California at San Diego, but pursued an entrepreneurial path. Following a successful series of investments in various ventures, Mr. W...... took a strong interest in biotechnology, where he is self-taught. He has since connected with leading biotechnology minds in San Diego and spear-headed their collaboration while garnering significant private investment. Mr. W...... hopes to improve the lives of patients with devastating diseases by organizing and leading teams of highly qualified individuals to develop innovative therapeutics. He further seeks to utilize the success of Batu Biologics and future endeavors to drive his thirst for scientific entrepreneurship, and to give back to the communities that inspire him.

Dimitri Theofilopoulos, J.D.
Chief Operating Officer
D......

D...... Theofilopoulous oversees operations and legal matters for Batu Biologics. D...... was in-house business counsel for consulting transactions and research compliance at The Scripps Research Institute from June 2010 – March 2013. Prior to that, he practiced employment and healthcare law. D...... holds a from USC School of Law and a B.A. in History from UCLA. He has also published The Bar Exam Memorization Book, a useful study aid for the bar exam.

Hong Ma, MD, Ph.D., M.B.A.
Vice President Business Development
Hong M......

Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

Gerry Berg
Chief Financial Officer
Gerry B......

Mr. B...... has over 30 years of senior management experience working with private and public companies. Mr. B...... has served a number of public companies as their Chief Executive Officer, President, Chief Financial Officer or as a financial consultant. He has also served on the Board of Directors for a number of public companies. Mr. B...... began his career as a Certified Public Accountant with the firm of Deloitte & Touche (Deloitte). He served as Audit Manager for the Buick Motor Division of General Motors Corporation as one of his primary assignments. Mr. B...... holds a Bachelors of Arts in Accounting from Walsh College where he graduated Cum Laude. Mr. B...... became a Certified Public Accountant (CPA) in the State of Michigan in 1979 and in the State of California in 1984.

Vijay Mahant, Ph.D.
Science/Scientist
Vijay M......

Dr. Mahant graduated from LUT (UK) and he received his second post-doctorate from UT Health Science Center at Houston/MD Anderson, TX, USA). Dr. Mahant is a scientist and an entrepreneur with 30 years of experience in immuno- and molecular diagnostics. He has held executive positions and he is founder/co-founder of diagnostic companies with diverse experiences in RD, worked with hospitals /medical institutes such as Mayo Clinic (‘87-’89, “New Generation” ultra-sensitive TSH test (evaluated and validated by Dr. George Klee , President of American Thyroid Association ) and worked (2005) with Long Beach Memorial Hospital in setting up a molecular diagnostic lab. Dr. Mahant has been involved in fund raisings, Initial Public Offerings (IPOs) and he has 25 issued patents and 15 patents pending; he has authored and/or co-authored publications. He has developed more than 35 products with multi million dollars in revenues.

Santosh Kesari, M.D., Ph.D., FANA
Chief Physician/Medical Officer
Santosh K......

Dr. Kesari is one of “America’s Top Doctors” selected by Castle Connolly Medical Ltd. He is among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd. Each year, Castle Connolly surveys thousands of physicians and other healthcare professionals and asks them to identify excellent doctors in every specialty in their region and throughout the nation for their Top Doctors™ distinction. Dr. Kesari is often called upon by the media to comment on neurological issues and the non-surgical treatment of brain tumors. Dr. Kesari is currently the Chair and Professor of the Department of Translational Neurosciences and Neurotherapeutics at the John Wayne Cancer Institute.

17%

Funding Goal $3,000,000
Funding Raised So Far $0
Funding Commitments $500,000
Funding Remaining $2,500,000
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents

Contact

Batu Biologics, Inc.

San Diego, CA 92121, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).